Mesoblast receives FDA clearance for Duchenne muscular dystrophy trial
Go back to Mesoblast receives FDA clearance for Duchenne muscular dystrophy trial| Management Of Environmental Solutions & Technology (NASDAQ: MESO) | Delayed: 15.40 +1.03 (7.17%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $14.37 | 52 Week High | $10.89 | |||
| Open | $14.95 | 52 Week Low | $3.50 | |||
| Day High | $15.66 | P/E | N/A | |||
| Day Low | $14.95 | EPS | $0.00 | |||
| Volume | 244,037 | |||||
